128 related articles for article (PubMed ID: 38296226)
1. The impact of sodium-glucose cotransporter-2 inhibitors on outcome of patients with diabetes mellitus and colorectal cancer.
Chiang CH; Chiang CH; Hsia YP; Jaroenlapnopparat A; Horng CS; Wong KY; Wang SS; Chang YC; Chen BS; Luan YZ; Wang CH; Neilan TG; Chiang CH; Peng CM; Shiah HS
J Gastroenterol Hepatol; 2024 May; 39(5):902-907. PubMed ID: 38296226
[TBL] [Abstract][Full Text] [Related]
2. Impact of sodium-glucose cotransporter-2 inhibitors on heart failure and mortality in patients with cancer.
Chiang CH; Chiang CH; Chiang CH; Ma KS; Peng CY; Hsia YP; Horng CS; Chen CY; Chang YC; See XY; Chen YJ; Wang SS; Suero-Abreu GA; Peterson LR; Thavendiranathan P; Armand P; Peng CM; Shiah HS; Neilan TG
Heart; 2023 Feb; 109(6):470-477. PubMed ID: 36351793
[TBL] [Abstract][Full Text] [Related]
3. Decreased risk of renal cell carcinoma in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors.
Chiu CH; Wang WY; Chen HY; Liao PL; Jong GP; Yang TY
Cancer Sci; 2024 Jun; 115(6):2059-2066. PubMed ID: 38572526
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of sodium-glucose cotransporter 2 inhibitors for renal prognosis and mortality in diabetes patients with heart failure on diuretics.
Weng YF; Chen CY; Hwang SJ; Huang YB
Kaohsiung J Med Sci; 2023 Apr; 39(4):416-425. PubMed ID: 36625282
[TBL] [Abstract][Full Text] [Related]
5. Sodium-Glucose Cotransporter 2 Inhibitors in South Australia: The Magic Before the Fame.
Tan JY; Chew DP; Lambrakis K; Tiver KD; Gnanamanickam ES; Muthuranjan C; Stranks SN; De Pasquale CG
Heart Lung Circ; 2023 Nov; 32(11):1369-1377. PubMed ID: 37914540
[TBL] [Abstract][Full Text] [Related]
6. Sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors on new-onset overall cancer in Type 2 diabetes mellitus: A population-based study.
Chung CT; Lakhani I; Chou OHI; Lee TTL; Dee EC; Ng K; Wong WT; Liu T; Lee S; Zhang Q; Cheung BMY; Tse G; Zhou J
Cancer Med; 2023 Jun; 12(11):12299-12315. PubMed ID: 37148547
[TBL] [Abstract][Full Text] [Related]
7. Sodium-Glucose Cotransporter-2 Inhibitors and Nephritis Among Patients With Systemic Lupus Erythematosus.
Yen FS; Wang SI; Hsu CC; Hwu CM; Wei JC
JAMA Netw Open; 2024 Jun; 7(6):e2416578. PubMed ID: 38865122
[TBL] [Abstract][Full Text] [Related]
8. Elevated circulating level of β-aminoisobutyric acid (BAIBA) in heart failure patients with type 2 diabetes receiving sodium-glucose cotransporter 2 inhibitors.
Katano S; Yano T; Kouzu H; Nagaoka R; Numazawa R; Yamano K; Fujisawa Y; Ohori K; Nagano N; Fujito T; Nishikawa R; Ohwada W; Katayose M; Sato T; Kuno A; Furuhashi M
Cardiovasc Diabetol; 2022 Dec; 21(1):285. PubMed ID: 36539818
[TBL] [Abstract][Full Text] [Related]
9. Diabetic patients with and without sodium-glucose cotransporter-2 inhibitors use and cataract risk: real-world observational investigation.
Hu WS; Lin CL
Acta Diabetol; 2023 Jul; 60(7):981-987. PubMed ID: 37083962
[TBL] [Abstract][Full Text] [Related]
10. Association of Continued Use of SGLT2 Inhibitors From the Ambulatory to Inpatient Setting With Hospital Outcomes in Patients With Diabetes: A Nationwide Cohort Study.
Singh LG; Ntelis S; Siddiqui T; Seliger SL; Sorkin JD; Spanakis EK
Diabetes Care; 2024 Jun; 47(6):933-940. PubMed ID: 38051789
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor: Results From the EASEL Population-Based Cohort Study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World).
Udell JA; Yuan Z; Rush T; Sicignano NM; Galitz M; Rosenthal N
Circulation; 2018 Apr; 137(14):1450-1459. PubMed ID: 29133607
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients: A Propensity Score-Matched Study in Hong Kong.
Lee S; Zhou J; Leung KSK; Wai AKC; Jeevaratnam K; King E; Liu T; Wong WT; Chang C; Wong ICK; Cheung BMY; Tse G; Zhang Q
Cardiovasc Drugs Ther; 2023 Jun; 37(3):561-569. PubMed ID: 35142921
[TBL] [Abstract][Full Text] [Related]
13. Incident heart failure and myocardial infarction in sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitor users.
Zhou J; Lee S; Leung KSK; Wai AKC; Liu T; Liu Y; Chang D; Wong WT; Wong ICK; Cheung BMY; Zhang Q; Tse G
ESC Heart Fail; 2022 Apr; 9(2):1388-1399. PubMed ID: 35132823
[TBL] [Abstract][Full Text] [Related]
14. Beneficial effects of sodium glucose cotransporter 2 inhibitors on left ventricular mass in patients with diabetes mellitus.
Kosugi D; Inaba H; Kaido Y; Ito S; Hirobata T; Toyofuku M; Matsuoka T; Inoue G
J Diabetes; 2021 Nov; 13(11):847-856. PubMed ID: 34231959
[TBL] [Abstract][Full Text] [Related]
15. Psychiatric disorders in patients with type 2 diabetes mellitus on sodium-glucose cotransporter-2 inhibitors-a nationwide retrospective cohort study.
Hu WS; Lin CL
Naunyn Schmiedebergs Arch Pharmacol; 2024 Jan; 397(1):575-581. PubMed ID: 37490120
[TBL] [Abstract][Full Text] [Related]
16. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis.
Mui JV; Zhou J; Lee S; Leung KSK; Lee TTL; Chou OHI; Tsang SL; Wai AKC; Liu T; Wong WT; Chang C; Tse G; Zhang Q
Front Cardiovasc Med; 2021; 8():747620. PubMed ID: 34746262
[No Abstract] [Full Text] [Related]
17. Comparing benefits from sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in randomized clinical trials: a network meta-analysis.
Sabouret P; Bocchino PP; Angelini F; D'Ascenzo F; Galati G; Fysekidis M; DE Ferrari GM; Fischman DL; Bhatt DL; Biondi-Zoccai G
Minerva Cardiol Angiol; 2023 Apr; 71(2):199-207. PubMed ID: 35195376
[TBL] [Abstract][Full Text] [Related]
18. Sodium-glucose cotransporter-2 inhibitors use and the risk of gout: a systematic review and meta-analysis.
Lai SW; Hwang BF; Kuo YH; Liu CS; Liao KF
Front Endocrinol (Lausanne); 2023; 14():1158153. PubMed ID: 37288295
[TBL] [Abstract][Full Text] [Related]
19. The impact of weight loss related to risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium-glucose cotransporter 2 inhibitor.
Chan YH; Chen SW; Chao TF; Kao YW; Huang CY; Chu PH
Cardiovasc Diabetol; 2021 Apr; 20(1):93. PubMed ID: 33941171
[TBL] [Abstract][Full Text] [Related]
20. Association of Sodium-Glucose Cotransporter 2 Inhibitor vs Dipeptidyl Peptidase-4 Inhibitor Use With Risk of Incident Obstructive Airway Disease and Exacerbation Events Among Patients With Type 2 Diabetes in Hong Kong.
Au PCM; Tan KCB; Lam DCL; Cheung BMY; Wong ICK; Kwok WC; Sing CW; Cheung CL
JAMA Netw Open; 2023 Jan; 6(1):e2251177. PubMed ID: 36648944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
